非酶糖基化抑制剂的体外筛选方法  

In vitro screening of nonenzyme glycation inhibitor

作　　者：邓洪斌[1] 崔大鹏[1] 冯艳春[1] 李电东[1] 

机构地区：[1]中国协和医科大学中国医学科学院医药生物技术研究所,北京100050

出　　处：《中国新药杂志》2004年第1期34-38,共5页Chinese Journal of New Drugs

基　　金：国家重点基础研究发展规划课题基金资助项目(G2000057010);国家自然科学基金项目(30070827)

摘　　要：目的:建立非酶糖基化抑制剂(NEGI)的体外筛选模型并筛选NEGI。方法:依据非酶糖基化(NEG)致衰老假说,用酶基糖基化终产物(AGE)多克隆抗体建立体外NEGI筛选模型。采用竞争性AGE-ELISA方法定量测定AGE的含量。结果:从60余种中草药组分、合成化合物中筛选得到了3种NEGI,AG2070为化学合成的化合物,INEG-1和INEG-2都属于中药多糖,在结构上与其他NEGI都不同。这3种抑制剂在体外实验中均显示出明显的抑制AGE形成的能力。结论:NEGI的体外筛选模型是可行的。Objective:To screen in vitro nonenzyme glycation inhibitor (NEGI). Methods:A model for in vitro screening of NEGI was established by use of polyclonal antibody and the advanced glycation endproduct (AGE) was measured by competitive AGE-ELISA method. Results: 3 NEGI were found from over 60 Chinese traditional herbal medicines. Among them AG2070 was a synthesized compound, and both INEG-1 and INEG-2 were belong to polysaccharides from traditional Chinese medicine. All the three showed remarkable inhibitory effect on AGE formation. Conclusion: The model for in vitro screening of NEGI is feasible.

关 键 词：非酶糖基化抑制剂 晚期糖基化终产物 筛选 氨基胍 

分 类 号：R965.1[医药卫生—药理学] R285.5[医药卫生—药学]